NADPH oxidase-IN-1

Modify Date: 2025-08-25 00:31:42

NADPH oxidase-IN-1 Structure
NADPH oxidase-IN-1 structure
Common Name NADPH oxidase-IN-1
CAS Number 2762405-17-2 Molecular Weight 373.51
Density N/A Boiling Point N/A
Molecular Formula C20H27N3O2S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of NADPH oxidase-IN-1


NADPH oxidase-IN-1 is an orally active NADPH Oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].

 Names

Name NADPH oxidase-IN-1

 NADPH oxidase-IN-1 Biological Activity

Description NADPH oxidase-IN-1 is an orally active NADPH Oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].
Related Catalog
Target

NOX2:1.9 μM (IC50)

NOX4:2.47 μM (IC50)

In Vitro NADPH oxidase-IN-1 (化合物11) 可以穿过血脑屏障,Pe 值为 13.6 (10-6 cm/s),由平行人工膜透性试验 (PAMPA) 测定[1]。 NADPH oxidase-IN-1 (1 nM-10 mM; 30min) 抑制 LPS 诱导 BV2 小胶质细胞产生 ROS,并呈剂量依赖性[1]。 NADPH oxidase-IN-1 (10 μM; 24 h) 抑制 BV2 细胞中促炎细胞因子的 mRNA 表达[1]。 NADPH oxidase-IN-1 (1 nM-10 mM; 24 h) 也抑制 BV2 细胞的激活和迁移[1]。 RT-PCR[1] Cell Line: BV2 microglial cells Concentration: 10 μM Incubation Time: 24 hours Result: Inhibited the mRNA expression of pro-inflammatory cytokines (iNOS, IL-1β, TNFα) in BV2 cells. Cell Migration Assay [1] Cell Line: BV2 microglial cells Concentration: 10 μM Incubation Time: 24 hours Result: Ameliorated inflammatory response and migration of microglia.
In Vivo NADPH oxidase-IN-1 (化合物11) (30 mg/kg; 口服给药; 每日给药, 共 4 周) 在患帕金森疾病的小鼠模型中,能够减弱 MPTP 诱导的小胶质细胞激活,减少多巴胺能神经元损伤[1]。 NADPH oxidase-IN-1 通过静脉注射 (10-300 mg/kg; 单次给药) 和灌胃 (10- 1000mg /kg;单次剂量) 处理,对雄性和雌性小鼠都是安全的[1]。 在大鼠中的药代动力学特征 Parameters C0 (μg/mL) Cmax (μg/mL) t1/2 (h) Tmax (h) AUClast (μg/h/mL) ke (1/h) Vd (L) Vd/F (L) Cl (L/h) Cl/F (L/h) F (%) IV (2 mg/kg) 1.70 0.79 0.468 1.32 0.211 0.217 PO (10 mg/kg) 0.609 5.01 [0.083-2] 1.31 0.170 1.99 0.341 56.0 PO (20 mg/kg) 0.783 6.13 [0.67-2] 4.16 0.159 1.82 0.217 88.9
References

[1]. Shim S, et al. Discovery of a NADPH oxidase inhibitor,(E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl) amino) benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease[J]. European Journal of Medicinal Chemistry, 2022, 244: 114854.

 Chemical & Physical Properties

Molecular Formula C20H27N3O2S
Molecular Weight 373.51
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.